Trial results

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

NCT06671587 on ClinicalTrials.gov · last registry update 2026-03-17

An unusually large phase 4: 678 participants, more than double the 75 typical for the stage. Its estimated completion date, 18 September 2026, has passed with no update to the record. Primary outcome, as filed: Superiority of mean change in the percentage of TIR [3.9-10.0 mmol/L (70-180 mg/dL)]. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

RECRUITING

Phase

P4

Drug

lixisenatide

Adlyxin, Soliqua

Sponsor

Sanofi

Sponsor type

Industry

Enrollment

678

Started

2024-12-10

Primary completion

2026-09-18 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Superiority of mean change in the percentage of TIR [3.9-10.0 mmol/L (70-180 mg/dL)]

Conditions studied

Type 2 Diabetes (T2D)

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.